Drug intelligence / Profile preview

CAM2056

Development stage: Unknown
Lead developer: Camurus
Modality: Peptides
Administration: Subcutaneous

Overview

CAM2056 is an investigational long-acting monthly subcutaneous depot formulation of semaglutide being developed by Camurus for the treatment of obesity and overweight. It utilizes Camurus' proprietary FluidCrystal® technology to enable extended-release and sustained delivery of the active ingredient. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works to reduce body weight by decreasing appetite and energy intake. The drug is designed for monthly administration, potentially improving treatment adherence compared to existing weekly formulations. Clinical results from a Phase 1b trial demonstrated significant weight reduction with safety and tolerability profiles consistent with other semaglutide products.

Other names: semaglutide monthly depot

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on CAM2056.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAM2056.

Explore the full profile